Announcement • Jul 31
Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.75 million. Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.75 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 55,000,000
Price\Range: AUD 0.05
Discount Per Security: AUD 0.003
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Announcement • Jul 04
Nasdaq to Delist ADS of Advanced Health Intelligence The Nasdaq Stock Market announced that it will delist the American Depositary Shares of Advanced Health Intelligence Ltd. Advanced Health Intelligence’s security was suspended on July 30, 2024 and has not traded on Nasdaq since that time. Announcement • Dec 02
Advanced Health Intelligence Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.272075 million. Advanced Health Intelligence Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.272075 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,222,222
Price\Range: AUD 0.0675
Discount Per Security: AUD 0.00405
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,284,441
Price\Range: AUD 0.0675
Discount Per Security: AUD 0.00405
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,153,701
Price\Range: AUD 0.0675
Discount Per Security: AUD 0.00405
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Announcement • Oct 30
Advanced Health Intelligence Ltd, Annual General Meeting, Nov 29, 2024 Advanced Health Intelligence Ltd, Annual General Meeting, Nov 29, 2024. Location: at steinepreis paganin, level 14, qv1, 250 st george`s terrace, perth wa 6000 Australia Announcement • Jul 30
Advanced Health Intelligence Ltd(NasdaqCM:AHI) dropped from NASDAQ Composite Index AHI has been dropped from NASDAQ Composite Index Announcement • Apr 16
Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million. Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,000,000
Price\Range: AUD 0.0675
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Announcement • Feb 27
Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,000,000
Price\Range: AUD 0.1
Transaction Features: Subsequent Direct Listing Announcement • Dec 02
Advanced Health Intelligence Ltd to Launch Medically Approved Mobile Phone-Based Atrial Fibrillation Assessment Advanced Health Intelligence Ltd. announced that the Company will be expanding the current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service in quarter 2 of 2024 after signing a binding agreement with QOMPIUM NV. AHI is thrilled to be expanding the biometric capabilities the company is bringing to the global healthcare system with the introduction of AF-Scan. This ground-breaking mobile phone-based solution is set to revolutionise the detection and management of Atrial Fibrillation (AF). This innovative technology is poised to offer unprecedented accessibility and convenience, opening new possibilities in AF monitoring for global populations. With the increasing prevalence of AF and its substantial impact on healthcare systems and economies, AF-Scan will emerge as a critical tool for individuals, healthcare professionals, and public health initiatives. With widespread Approval and Accessibility, Qompium technology has received approval as software as a medical device in multiple countries, including Australia, the European Union (EU), the United Kingdom (UK), the United Arab Emirates (UAE), Saudi Arabia, Singapore, and the United States by the Food and Drug Administration (FDA). This extensive approval further underscores the reliability and credibility of assisting with AF detection and is a unique and sought-after addition to the AHI biometric assessment offering. Atrial Fibrillation (af) is a prevalent cardiac condition with a substantial impact on public health. AHI's BHA harnesses the power of PPG collected via the flashlight and camera on smartphone to provide downstream services such as AF-Scan with the necessary biometric signals. The solution is backed by a medically certified AI algorithm that swiftly analyses the PPG measurements it captures. This analysis generates a comprehensive set of graphical data in the form of a report to be consumed by a physician. One can share this report with physician, making discussions about heart health more productive. AF diagnosis is challenging, often leading to underdiagnosis and misdiagnosis, emphasizing the need for proactive monitoring. AF-Scan is a mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide. By empowering individuals to monitor their heartythm, AF-Scan aims to reduce the incidence of complications like strokes and heart failure, optimising healthcare spending. This level of accessibility can potentially transform how approach cardiac health. AI will incorporate the AF-Scan into biometric health assessment platform. This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers. This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing to offer a holistic view of their well-being. AF-Scan offers a game-changing alternative in a market where traditional AF screening and monitoring methods often involve cumbersome processes and visits to healthcare facilities. By combining the mobile phone with advanced biometric health assessment platform, provide individuals with a powerful tool that empowers them to take control of their health like never before. As the roll out AF-Scan and integrate it into existing platform, are not just launching a product but pioneering a product but pioneering a product. Announcement • Nov 06
Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million. Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 10,749,996
Price\Range: AUD 0.11
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,245,454
Price\Range: AUD 0.11
Transaction Features: Subsequent Direct Listing Announcement • Nov 01
Advanced Health Intelligence Ltd. announced delayed 20-F filing On 10/31/2023, Advanced Health Intelligence Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Announcement • Oct 19
Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023 Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023, at 10:30 W. Australia Standard Time. Location: Steinepreis Paganin, Level 4, 16 Milligan Street, Perth WA 6000 Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2023 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of remuneration report; to election of director Jacqueline yee; to re-election of director Dato low koon poh; to re-election of director Mike melby; to issue of shares to related party Nicholas prosser; to issue of shares to related party Mike melby; to approval of 7.1A mandate; to adoption of employee securities incentive plan; to ratification of prior issue of lender shares; to ratification of prior issue of consultant shares; to ratification of prior issue of supplier shares; to ratification of prior issue of placement shares listing rule 7.1; to ratification of prior issue of placement shares listing rule 7.1A; to ratification of prior issue of lead manager options; and to consider other issues. Announcement • Sep 14
Advanced Health Intelligence Ltd. announced that it has received AUD 1.5 million in funding Advanced Health Intelligence Ltd. announced a private placement of unsecured convertible loan facility for the gross proceeds of AUD 1,500,000 on September 12, 2023. The loan carry interest rate of 10% per annum and is compounded quarterly in arrears and will mature after 24 months from the date of signing. The investors may elect to redeem the outstanding principal amount and interest on the loans in cash on the Maturity Date. The loans and interest may be converted into fully paid ordinary shares at the investor’s election, at a conversion price equal to AUD 0.30 per share. The transaction is subject to shareholders approval. Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.072 loss per share (vs AU$0.13 loss in FY 2022) Full year 2023 results: AU$0.072 loss per share (improved from AU$0.13 loss in FY 2022). Net loss: AU$13.3m (loss narrowed 34% from FY 2022). Revenue is forecast to grow 118% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. New Risk • Aug 31
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$11m free cash flow). Share price has been highly volatile over the past 3 months (49% average daily change). Revenue is less than US$1m (AU$494k revenue, or US$320k). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (AU$46.8m market cap, or US$30.3m). Announcement • Jun 15
Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million. Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: AUD 0.25
Discount Per Security: AUD 0.015
Transaction Features: Subsequent Direct Listing New Risk • Jun 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 48% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$11m free cash flow). Share price has been highly volatile over the past 3 months (48% average daily change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (AU$494k revenue, or US$334k). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (AU$78.7m market cap, or US$53.3m). Reported Earnings • Mar 03
First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.10 loss in 1H 2022) First half 2023 results: AU$0.024 loss per share (improved from AU$0.10 loss in 1H 2022). Net loss: AU$3.91m (loss narrowed 73% from 1H 2022). Revenue is forecast to grow 123% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Software industry in Australia. Over the last 3 years on average, earnings per share has fallen by 24% per year and the company’s share price has also fallen by 24% per year. Breakeven Date Change • Jan 31
Forecast breakeven date pushed back to 2025 The analyst covering Advanced Health Intelligence previously expected the company to break even in 2023. New forecast suggests losses will reduce by 54% per year to 2024. The company is expected to make a profit of AU$18.4m in 2025. Average annual earnings growth of 81% is required to achieve expected profit on schedule. Board Change • Jan 31
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CEO & Executive Director Scott Montgomery was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 17
Full year 2022 earnings released: AU$0.15 loss per share (vs AU$0.11 loss in FY 2021) Full year 2022 results: AU$0.15 loss per share (further deteriorated from AU$0.11 loss in FY 2021). Net loss: AU$22.6m (loss widened 61% from FY 2021). Revenue is forecast to grow 101% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Software industry in Australia. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Breakeven Date Change • Sep 13
Forecast breakeven date pushed back to 2025 The analyst covering Advanced Human Imaging previously expected the company to break even in 2023. New forecast suggests losses will reduce by 55% per year to 2024. The company is expected to make a profit of AU$18.4m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule. Reported Earnings • Sep 05
Full year 2022 earnings released: AU$0.13 loss per share (vs AU$0.11 loss in FY 2021) Full year 2022 results: AU$0.13 loss per share (further deteriorated from AU$0.11 loss in FY 2021). Net loss: AU$20.6m (loss widened 46% from FY 2021). Revenue is forecast to grow 108% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Software industry in Australia. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 02
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: AU$0.10 loss per share (down from AU$0.046 loss in 1H 2021). Net loss: AU$14.5m (loss widened 165% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 42,742%, compared to a 65% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Breakeven Date Change • Mar 01
Forecast to breakeven in 2023 The analyst covering Advanced Human Imaging expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$6.40m in 2023. Average annual earnings growth of 112% is required to achieve expected profit on schedule. Reported Earnings • Oct 04
Full year 2021 earnings released: AU$0.11 loss per share (vs AU$0.052 loss in FY 2020) Full year 2021 results: Net loss: AU$14.1m (loss widened 161% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 41% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Sep 15
Advanced Human Imaging Limited Announces the Submission of the Health Cube App into the Top 10 China App Stores with Tinjoy Biotech Limited Advanced Human Imaging Limited announced the submission of the Health Cube app, which contains the WinScan app, into the top 10 China app stores, with Tinjoy Biotech Limited. AHI is happy to confirm that Tinjoy have now submitted "The Health Cube" application to multiple Android and Apple app stores for a scheduled release this week of the application into the China market. China has 29 app stores, with the first 10 app stores to launch being Huawei App Market, Tencent My App, Oppo Software Store, VIVO App Store, MIUI App Store, 360 Mobile Assistant, Baidu Mobile Assistant, Samsung App Store, PP Assistant and Wandoujia. These stores see a combined audience of over 1,139 billion users and over 248 million active daily users. The Health Cube only offered an annual subscription at CNY 310 (AUD 64.86) which attracted over 144,000 pre-registrations. Under the 12-month subscription, subscribers have unlimited BodyScans and 52 FaceScans. In addition to the 12-month subscription, Tinjoy has identified a need to offer 2 additional subscription levels, a 1-month subscription for CNY 33 (AUD$6.94) and a 3-month subscription for CNY 99 (AUD 20.83), which will be offered as part of a bundled offering to Tinjoy's prebiotic purchasers, which currently exceed 1,000,000 individual purchases per month. Tinjoy will now issue download activation codes to the pre-registrations and commence activation of these accounts. Under the terms of the agreement with AHI, Tinjoy will pay AHI 70% of the revenue generated from the subscriptions. With the previously confirmed preregistration number having grown to over 144,391 potential users, Tinjoy have achieved a total revenue commitment from the users of CNY 44,761,210 (AUD 9,365,200). Importantly, investors should be aware, as previously announced, the agreement with Tinjoy is a gross revenue share arrangement with a 70/30 split, with AHI receiving 70% of the revenue. There are no deductions from the revenue generated by Tinjoy. The collection of the preregistration payments will now be activated by Tinjoy upon the release of "The Health Cube" application to the registrants. AHI's arrangement with Tinjoy consists of billing events at the end of each month and payment is then due to AHI within 14 days of invoice. AHI will report to shareholders on a regular basis as Tinjoy confirm the conversion of registrants to paid users. Board Change • Sep 14
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Luisa Ingargiola was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 13
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Luisa Ingargiola was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 09
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Luisa Ingargiola was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 06
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Luisa Ingargiola was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 03
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Luisa Ingargiola was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 01
Full year 2021 earnings released: AU$0.11 loss per share (vs AU$0.052 loss in FY 2020) Full year 2021 results: Net loss: AU$14.1m (loss widened 161% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 67% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 28
Advanced Human Imaging Limited Announces Derma AI Embedded in the AHI DermaScan Receives CE Mark Clearance in the European Union for the Dermatology AI Component in CompleteScan Advanced Human Imaging Limited ("AHI" or the "Company") announced the Derma AI embedded in the AHI DermaScan has received CE Mark clearance in the European Union for the dermatology AI component in CompleteScan. The Derma AI component (DermaScan AI) can accurately classify skin conditions from an image captured on a standard smartphone camera. Using the large proprietary database of its kind in the world, the Derma AI can classify 588 common or rare skin conditions in 133 categories – including all categories of skin cancer. In April, AHI announced a significant equity stake in Triage and a deal to integrate Derma AI into the AHI-owned and patented CompleteScan SaaS platform. The integrated product, known as DermaScan, will empower dermatologists, clinicians, physicians, and nurses to get an instant second opinion and better identify dermatologic conditions using only a smartphone. Announcement • May 27
Advanced Human Imaging's DermaScan AI Receives Medical Device Approval 27 EU Countries (CE Mark) Advanced Human Imaging Limited informed shareholders with the granting of European medical device approval European Conformity (CE) for the 27 countries of the EU, allowing the Derma AI component in the CompleteScan offering a medical device approval. The Derma AI has been developed and patented by AHI partner's Triage. The granting of the CE approval is a substantive milestone for the Company and for the partnership that AHI has with Triage, Because Triage has the world's largest dermatological Artificial Intelligence (AI) system/database of skin conditions, it can identify through mobile device images in only seconds. The database is not only the largest of its kind in the world, but also the most comprehensive. The DermaScan AI engine identifies 588 skin conditions in 133 categories. Importantly the application can identify all categories of skin lesions leading to cancers. The 133 categories of skin conditions have been developed over the last 6 years, which covers 99% of the global dermatological conditions marketplace and has been built in consultation with Stanford University and Dermatologists around the world listing the conditions that they treat. The web application was released in 2020 and has had 170,000 users who have used the application over 650,000 times. Note that 12% of these users are clinicians deploying this new standard of care in a clinical environment. The Derma AI is now being used in over 200 countries worldwide, allowing skin conditions to be detected and identified with all skin types and tones across all ethnicities. The accuracy of the sophisticated DermaScan AI engine has been tested against dermatologists and has proven to be more accurate, more often than a dermatologist. In a recent study in Canada conducted with 157 Dermatologists, the application outperformed 154 dermatologists and drew even with 3 on identifying a cross-section of conditions against images. The competitive landscape is narrow in the digital space that Triage dominates. The companies of note that are predominant in the space are IBM, Google, and SkinVision (with 4 conditions only in Cancer). This superiority in itself is a credit to Triage with its advanced Derma AI and vast coverage of conditions and categories. Triage has patents issued and pending globally for its technology and has had prior art since 2014 protecting its process and its Derma AI engine. Triage has received medical device approval in Canada from the CMDR and now CE Mark for Europe, with FDA approval for the US expected in the near future 2021. The Derma AI is being combined into the AHI-owned CompleteScan platform. The AHI team with their on-device expertise is advancing the Derma AI to be an on-device, ready-to-use application for consumers all over the world. Announcement • May 05
Advanced Human Imaging Limited to Launch BodyScan in Original Fit Factory's Fitness App Truconnect to Audience of 150+ Million Advanced Human Imaging Limited announced that it will launch its smartphone-based technology, BodyScan, to 150+ million audience of The Original Fit Factory's flagship fitness app, TRUCONNECT, on May 8, 2021. That is when TRUCONNECT's users will be offered free 36-hour use of BodyScan. The launch follows AHI's recent completed integration agreement with The Original Fitness Factory ("TOFF"). TRUCONNECT is a health, fitness and wellbeing app that is available on Apple, Huawei and Android smartphones. TRUCONNECT offers unique access to content from world-renowned fitness experts, athletes and celebrities – providing users with the flexibility and convenience to stream workouts with distinguished experts. TRUCONNECT has an audience of more than 150 million people through the partners around the globe such as fitness expert Amanda Cerny, MMA superstar Georges St-Pierre and Bollywood actress Jacqueline Fernandez. AHI's patented BodyScan technology, now integrated with TRUCONNECT, allows individuals, via an automated system, to take a series of images of themselves using a smartphone camera which delivers accurate and repeatable measurements of body dimensions and composition. These measurements allow users to understand the physical changes they are undergoing through diet, exercise and lifestyle. Further, the images that AHI captures also provide the individual with an understanding of their risk related to certain chronic diseases including obesity and diabetes. Is New 90 Day High Low • Mar 03
New 90-day high: AU$2.17 The company is up 104% from its price of AU$1.07 on 03 December 2020. The Australian market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is down 8.0% over the same period. Reported Earnings • Mar 03
First half 2021 earnings released: AU$0.046 loss per share (vs AU$0.029 loss in 1H 2020) The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: AU$577.2k (up AU$485.2k from 1H 2020). Net loss: AU$5.47m (loss widened 86% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Announcement • Feb 26
MyFiziq Limited to Appoint New US Board Members in Readiness for Nasdaq MyFiziq is very pleased to have received the acceptance from Edward Greissing Jr and Luisa Ingargiola to be appointed to the board of directors of the company. Both appointees will join the board of MyFiziq upon the official listing onto the NASDAQ. Greissing will be a Non-Executive Director and Ingargiola with be a Non-Executive Director and Chair of the company's Audit Committee. Mr. Edward Greissing is a Strategic Advisor and Senior Fellow with the Milken Institute. Previously he was the Executive Director for the Center of Public Health at the Milken Institute. Luisa currently serves as Chief Financial Officer of a NASDAQ biotech firm and Audit Chair of several Public companies including AgEagle, Vision Marine and Progress Acquisition Corporation. Announcement • Feb 24
MyFiziq Names William Bradford as New Global Chief Business Officer in USA The Board of MyFiziq Limited announced that it has appointed William Bradford in a full-time capacity as the new Global Chief Business Officer for MyFiziq in the USA. Most recently, Bradford was Chief Digital Officer at Beachbody, LLC. Previously, he led the digital transformation of Fox Broadcasting from a traditional linear broadcast business to a multi-platform content service, with new monetization and customer engagement models. Is New 90 Day High Low • Feb 08
New 90-day high: AU$1.35 The company is up 62% from its price of AU$0.83 on 10 November 2020. The Australian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 1.0% over the same period. Announcement • Jan 23
MyFiziq Signs Marketing and Expansion Agreement with Bearn MyFiziq Limited update shareholders with today's funding agreement entered into with Bearn LLC (Bearn). MyFiziq and Bearn have been working together over the past 60 days formulating a marketing and expansion plan, to target both the delivery of 1,000,000 users and the required expansion to the Bearn platform to allow for the volume provisions required to support the large already existing pre-registered users. Bearn approached MyFiziq wanting to execute on a large-scale campaign to their pre-registered users. It was outlined by Bearn management that the scale of which they had received pre-registrations would not be possible based on the existing specifications of the Bearn platform. To achieve this outcome, Bearn required a small injection of development capital and then a further joint amount to execute on a direct to pre- registration onboarding campaign. Bearn presents a unique multi-sided vendor backed platform that allows for the gamification and engagemen of health with users. Users earn actual cash for improving their health, fitness and wellness. To date, Bear has been able to demonstrate a 75% retention rate of its users. Bearn is focused on partnering with companie that are looking to build retention through rewarding their consumers for achieving their fitness and weigh loss goals. Bearn is using its expert industry knowledge and global strategic networks to bring the world it innovative application to the mass market consumer through multiple industries such as Health, and wellnes providers and many of the world's largest wearables manufacturers and distributors. Bearn presents a unique multi-sided vendor backed platform that allows for the gamification and engagement of health with users. Users earn actual cash for improving their health, fitness and wellness. To date, Bearn has been able to demonstrate a 75% retention rate of its users. Bearn is focused on partnering with companies that are looking to build retention through rewarding their consumers for achieving their fitness and weight loss goals. Bearn is using its expert industry knowledge and global strategic networks to bring the world its innovative application to the mass market consumer through multiple industries such as Health, and wellness providers and many of the world's largest wearables manufacturers and distributors. The MyFiziq technology is embedded into the Bearn application and ready to reach into the 56,000,000 pre- registered users they have acquired through their existing partnerships. With the new expanded platform integration, customers of Bearn are be able to access the MyFiziq technology, via the Bearn app, which is now available on the Apple App Store & Google Play Store. The Bearn application, with the MyFiziq in- app scanning capability, has been released on both iOS, and Android to deliver maximum reach into their current pre-registered users. Bearn and MyFiziq have completed the initial integration of the MyFiziq SDKs. Bearn's users are now able to track changes in their body shape, weight and health using the MyFiziq technology as they follow Bearn's coaching, fitness and nutritional programs. MyFiziq is an integral part of Bearn's rewards offering as the primary check point of dimensional and body composition change goals being achieved. Bearn users earn access to the MyFiziq tracking technology under the Bearn reward program where they will receive an ability to check their goals are being achieved each week through the dollars they have earned. MyFiziq will be paid USD 2.00 per scan from Bearn. In addition to this, the parties have agreed to also now offer a 12-month subscription at a cost of USD 3.99 a month when purchasing an annual subscription to the measurement functionality, totaling USD 47.88 per annum allowing unlimited scans. In just a few short years, Bearn has become a global player, securing contracts across multiple verticals, from health platforms, health, and fitness retailers to government bodies and some of the world's largest wearables manufacturers and gym chains. All of these partnerships have resulted in over 56,000,000 pre- registrations for the application, which now includes the MyFiziq platform capabilities. Announcement • Jan 22
MyFiziq Limited Announces Management Changes MyFiziq Limited informed shareholders regarding changes to the Board of MyFiziq Limited. As MyFiziq is progressing its US NASDAQ initiative, Non-Executive Chairman, Peter Wall will be stepping down from his role as Non-Executive Chairman. Current CEO and Founder, Vlado Bosanac, will take up the role as Executive Chairman and CEO for the transition to the US. Mr. Wall has been involved with the Company for the past 5 years as Non-Executive Chairman and will continue to work closely with MyFiziq and its transition to the US, through his law firm Steinepreis Paganin. MyFiziq is currently in discussions with several US based director candidates with an intention to bring them onto the Company as board members when it redomiciles to the US. Mr. Wall will step down as Non-Executive Chairman officially as of 22 January 2021. Announcement • Jan 06
Myfiziq Limited Releases Applications with Biomorphik Pty Ltd App with the Myfiziq Technology MyFiziq Limited provide an update to shareholders regarding the now released applications with Biomorphik Pty Ltd. ("Biomorphik") App with the MyFiziq technology. The App has now been released on both Google Play and Apple Store. In line with the initial product release, Biomorphik will commence a comprehensive B2C marketing strategy to draw users to the new platform with the first stage allowing people to monitor their bodies closely and pre-empt potential issues before they become prohibitive to the user's health. Under the terms of the commercial contracts, Biomorphik has given an undertaking to deliver to MyFiziq 100,000 active monthly users. In the event this target is not achieved, MyFiziq has a right to terminate the
agreements between the parties. Biomorphik will offer both a monthly subscription at AUD 22.99 per month for unlimited scans, as well as a yearly subscription payment option with a significant discount at AUD 142.99 per year for unlimited scans to consumers. Announcement • Oct 20
MyFiziq Limited Completes Definitive Agreements with MVMNT Inc MyFiziq Limited announced that the company has signed definitive agreements with MVMNT Inc. As MyFiziq's technology will be integrated into MVMNT's core mobile technology platform, the MyFiziq solution will be made available to all subscribers within MVMNT's branded digital training experiences. Commencing with 3 initial previously announced platforms, Mayweather Boxing & Fitness, McGregor F.A.S.T. and Fitocracy. The first MVMNT partners to integrate MyFiziq's technology include Floyd Mayweather Boxing and Fitness, McGregor Fast by Conor McGregor, and Fitocracy. With a current combined Instagram reach of over 50 million people globally between Floyd Mayweather and Conor McGregor, MVMNT is confident in the potential of its digital training offerings and the additional value that will be brought to fitness consumers by the integration of the MyFiziq technology. Announcement • Oct 14
MyFiziq Limited announced that it expects to receive AUD 5 million in funding MyFiziq Limited (ASX:MYQ) announced a private placement of 4,166,667 shares at a price of AUD 1.2 per share for gross proceeds of AUD 5,000,000 on October 14, 2020. The transaction will include participation from institutional and sophisticated investors. The company will also issue 4,166,667 options with a strike price of AUD 1.60 and expiring October 19, 2023. The company will pay AUD 2, 000 for expenses threshold and AUD 10,000 for DVP settlement. The transaction is expected to close on October 19, 2020. Announcement • Oct 06
Myfiziq Limited Signs Agreement with Nexus-Vita with USD 3.5 Million Guarantee MyFiziq Limited has signed a significant binding term sheet with Nexus Vita Pte Ltd. (Nexus-Vita), a Singapore-based health monitoring and management technology company. Nexus-Vita has developed a medical health monitoring, prevention, and engagement platform, that is the bridge between an individual's medical health and wellness management, with the aim of reducing health costs for individuals, governments and their healthcare providers and systems, globally. Nexus-Vita has created an application for individuals to track and manage all facets of their medical and health records, the platform is a proprietary health management and personal record keeping system in a single digital environment, where an individual can save their medical and health records in a single, easy-to-access digital platform. The data spans multiple environments from wearable data to training,nutrition, care programs, and allows the sharing of them with their doctor, healthcare provider, personal trainer or chronic disease management specialist. Nexus-Vita plans to drastically improve professional data sharing and management for users. This they believe will improve lifetime health, reduce the need for medical interventions, and save cost and resources for the user and health systems, through its partnership with MyFiziq and the use of the CompleteScan platform. Announcement • Oct 04
MyFiziq Limited Auditor Raises 'Going Concern' Doubt MyFiziq Limited filed its Annual on Sep 30, 2020 for the period ending Jun 30, 2020. In this report its auditor, Pannell Kerr Forster, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Reported Earnings • Oct 03
Full year earnings released - AU$0.052 loss per share Over the last 12 months the company has reported total losses of AU$5.40m, with losses widening by 24% from the prior year. Is New 90 Day High Low • Sep 29
New 90-day high: AU$1.32 The company is up 371% from its price of AU$0.28 on 01 July 2020. The Australian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 17% over the same period. Announcement • Sep 17
MyFiziq Limited Signs Definitive Agreements with Biomorphik to Accelerate A November 2020 Release MyFiziq Limited announced that it has executed definitive agreements with Biomorphik Pty Ltd. (Biomorphik), an Australian based behavioural change and technology company. Biomorphik has developed a medical health and wellness platform, that is the bridge between medical and health /wellness, with the aim of reducing health costs at all levels of society from the individual, to healthcare and insurance systems, and governments. Under the commercial terms of the definitive agreements, Biomorphik and MyFiziq have commenced working together to build and release an initial product by the 10th November 2020 using MyFiziq's new Body Scan OnDemand product which comprises a set of standalone iOS and Android applications, branded in Biomorphik colours, linked to Biomorphik's iOS and Android applications via cross app deep linking. In parallel with the accelerated time to market integration, the parties are also working on a full integration of the MyFiziq SDKs into the new platform that Biomorphik is developing. With a target release date of First Quarter 2021, the new MyFiziq integrated Biomorphik platform will also include multilanguage versions to target specific countries in Asia. Body Scan OnDemand is a new product provided by MyFiziq that utilises cross app linking to allow partner applications to invoke MyFiziq's scanning technology without having to directly integrate SDKs into their own application. Partner applications can simply use either an Apple Universal Link on iOS, or a Deep Link on Android, to route their users to MyFiziq's OnDemand service. On first launch, users are directed to either the Apple App Store or Google Play Store depending on their device and prompted to install the MyFiziq OnDemand application. On all subsequent invocations, users are quickly and easily routed between app contexts with no more than the click of a button in the matter of seconds. 